Infliximab for diarrhea or colitis from immune cancer therapy
Treatments studied
Part of Digestive system clinical trials.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and have a confirmed solid cancer tumor (not blood cancer)
- Have immune checkpoint treatment (anti–CTLA-4, anti–PD-1, or anti–PD-L1) within the last 12 weeks
- Have diarrhea or colitis that is moderate to severe, even after trying loperamide (if diarrhea is mild enough to qualify)
- Have no signs of a colon tear (perforation) and no current colonic infection
- Agree to consent, questionnaires, and diary tracking during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
This trial tests a new treatment, KAN-004, for people with diarrhea or colon inflammation caused by cancer immunotherapy. It aims to help manage these side effects.
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.